HONG KONG, Feb. 22, 2011 /PRNewswire-Asia/ -- Golden
Meditech Holdings Limited ("Golden Meditech" or the "Group,"
801.HK; 910801.TW), China's
leading integrated healthcare enterprise, is pleased to announce
that the Group's NYSE-listed affiliate, China Cord Blood
Corporation ("CCBC," -- CO.US) has made a major advancement in
domestic market expansion, via the inauguration of Zhejiang Cord
Blood Bank in Hangzhou, capital of
east China's Zhejiang Province, which will advance the
development of umbilical cord blood stem cell banking services in
Zhejiang while providing
professional, state-of-the-art services to the public in the
region.
The new cord blood bank in Zhejiang shall be under the direct governance
of the Provincial Ministry of Health as the only licensed operator.
CCBC will own 90% of Zhejiang Lukou Biotechnology Co., Ltd., a
jointly-established holding company between CCBC and the Zhejiang
Provincial Blood Center, which is the operator of the Zhejiang Cord
Blood Bank.
The new license will be the seventh provincial license issued by
the PRC Government under the "one-license-per-region" policy, and
the third obtained by the company since Beijing Municipal and
Guangdong Province.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group,
said, "As the founding and largest shareholder of CCBC, we are
delighted to see that CCBC has unveiled a number of very
encouraging developments thus far. Zhejiang has an annual birthrate of half a
million a year and a high per-capita GDP, which ranked fourth
amongst thirty-one provinces and municipalities in mainland
China after Shanghai, Beijing, and Tianjin, and its market potential is
substantial."
CCBC is the largest operator and the only one with multiple
licenses which, irrefutably, render the company as the market
leader in China. Prior to
obtaining the new license, CCBC has already had possession of the
exclusive operating licenses for both Beijing Municipal and
Guangdong Province on top of
approximately 20% stake in the exclusive operator in Shandong Province.
CCBC is also the single largest shareholder of Cordlife, the
largest cord blood banking operator in Southeast Asia that is listed on the
Australian Stock Exchange.
Mr. Kam reiterated, "We maintain a positive long term outlook
for the cord blood banking industry over China and the whole of the Asia-Pacific region, and are confident in
CCBC's management team and their ability to fully leverage the
excellent operational and marketing expertise, which will help to
sustain the company's high growth momentum and continue to
strengthen its leadership position of the industry."
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare device
and service operator, and the first medical device enterprise that
was publicly listed outside of the PRC on the Stock Exchange of
Hong Kong Limited (HKEx). Golden Meditech is a first-mover in
China, having established dominant
positions in medical devices and healthcare services markets over
the years, thanks to its strengths in innovation and market
expertise and the ability to capture emerging market opportunities.
Going forward, the Group will continue to pursue a leading position
in China's healthcare industry
both through organic growth and strategic expansion.
For enquiries, please contact:
|
|
Investor Relations
Department
|
|
Golden Meditech Holdings
Limited
|
|
Address:
|
48/F, Bank of China Tower, 1
Garden Road, Central, Hong Kong
|
|
Tel:
|
+852-3605-8180
|
|
Fax:
|
+852-3605-8181
|
|
Email:
|
ir@goldenmeditech.com
|
|
|
|
|
|
SOURCE Golden Meditech Holdings Limited